Mr. Geoffrey Lee reports

NAVCO PHARMACEUTICALS INC. ANNOUNCES STOCK OPTION GRANTS

Navco Pharmaceuticals Inc. has granted an aggregate of 3.9 million stock options to certain officers, directors and consultants of the company to purchase 3.9 million common shares in the capital of the company pursuant to the company's stock option plan. The options are exercisable at a price of five cents per share for a period of 10 years from the date of grant. The options shall vest immediately in accordance with the company's stock option plan dated for reference June 15, 2018.

About Navco Pharmaceuticals Inc.

Navco, based in Burlington, Ont., is building a leading market position in the use of nanotechnology to develop and commercialize novel products against bacteria, viruses, fungi and infectious diseases. Navco has a portfolio of patent-pending and Health Canada-approved products. The company's pipeline of applications is tailored to uniquely defend against pathogens utilizing new methods of action to capitalize on unmet health and product needs using natural and known compounds and nanoparticles with a high degree of efficacy. Target markets include human health and personal skin care, household and institutional products, and veterinary health.

We seek Safe Harbor.